Rilmenidine hemifumarate

• Supplier: Tocris Bioscience
• Catalog: 5359
• Prices: $139.00, $579.00
• Sizes: 10 mg, 50 mg
• Function Type: Agonist
• Cas Number: 207572-68-7
• Chemical Name: 2-[N-(Dicyclopropylmethyl)amino]oxazolinehemifumarate
• Formula: C10H16N2O.½C4H4O4
• Molecular Weight: 238.29
• Purity: >99 %
• Description: I 1 -imidazoline binding site selective ligand and α 2 -adrenoceptor agonist. Possesses greater I 1 vs α 2 selectivity than the prototypical compound, clonidine. Also thought to enhance autophagy; shown to increase LC3-II levels in PC12 cells.

Product References

Rilmenidine selectivity for imidazoline receptors in human brain. - Rilmenidine selectivity for imidazoline receptors in human brain.

Bricca G, Dontenwill M, Molines A, Feldman J, Tibirica E, Belcourt A, Bousquet P. Eur J Pharmacol. 1989 Apr 25;163(2-3):373-7.

Keeping an eye on the I site: imidazoline-preferring receptors. - Keeping an eye on the I site: imidazoline-preferring receptors.

Michel MC, Ernsberger P. Trends Pharmacol Sci. 1992 Oct;13(10):369-70.

Human brain imidazoline receptors: further characterization with [3H]clonidine. - Human brain imidazoline receptors: further characterization with [3H]clonidine.

Bricca G, Greney H, Zhang J, Dontenwill M, Stutzmann J, Belcourt A, Bousquet P. Eur J Pharmacol. 1994 Jan 1;266(1):25-33.

Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central - Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central

Mammoto T, Kamibayashi T, Hayashi Y, Yamatodani A, Takada K, Yoshiya I. Br J Pharmacol. 1996 Apr;117(8):1744-8.

Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. - Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.

Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, Jahreiss L, Fleming A, Pask D, Goldsmith P, O'Kane CJ, Floto RA, Rubinsztein DC. Nat Chem Biol. 2008 May;4(5):295-305.